TCON stock forecast
Our latest prediction for TRACON Pharmaceuticals Inc's stock price was made on the Nov. 15, 2023 when the stock price was at 0.17$.
In the short term (2weeks), TCON's stock price should underperform the market by -2.51%. During that period the price should oscillate between -13.01% and +9.73%.
In the medium term (3months), TCON's stock price should underperform the market by -8.12%. During that period the price should oscillate between -31.84% and +17.89%.Get email alerts
Create a solid portfolio with TCON
About TRACON Pharmaceuticals Inc
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
At the moment the company generates 20M USD in revenues.
On its last earning announcement, the company reported a loss of -0.57$ per share.
The book value per share is 1.24$
Three months stock forecastNov. 15, 2023
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|